PIXY321 + cyclophosphamide + doxorubicin + fluorouracil + leucovorin

This is a combination regimen consisting of PIXY321, cyclophosphamide, doxorubicin, fluorouracil, and leucovorin. - **PIXY321** is a recombinant fusion protein combining granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3), designed to stimulate multilineage hematopoiesis and reduce chemotherapy-induced myelosuppression[1][2][3][4]. - **Cyclophosphamide** is an alkylating agent that interferes with DNA replication and cell division[5]. - **Doxorubicin** is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II. - **Fluorouracil (5-FU)** is a pyrimidine analog antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. - **Leucovorin** enhances the binding of 5-FU to thymidylate synthase, increasing its cytotoxicity. This combination has been studied in oncology settings for its potential to improve hematologic recovery after chemotherapy by reducing neutropenia duration and severity while providing antitumor activity from the chemotherapeutic agents[1][3].